DK1218378T3 - Tert.-butyl-(7-methylimidazo[1,2-a]pyridin-3-yl) aminderivater - Google Patents

Tert.-butyl-(7-methylimidazo[1,2-a]pyridin-3-yl) aminderivater

Info

Publication number
DK1218378T3
DK1218378T3 DK00969439T DK00969439T DK1218378T3 DK 1218378 T3 DK1218378 T3 DK 1218378T3 DK 00969439 T DK00969439 T DK 00969439T DK 00969439 T DK00969439 T DK 00969439T DK 1218378 T3 DK1218378 T3 DK 1218378T3
Authority
DK
Denmark
Prior art keywords
methylimidazo
pyridin
tert
butyl
amine derivatives
Prior art date
Application number
DK00969439T
Other languages
Danish (da)
English (en)
Inventor
Corinna Maul
Bernd Sundermann
Hagen-Heinrich Hennies
Johannes Schneider
Matthias Gerlach
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Application granted granted Critical
Publication of DK1218378T3 publication Critical patent/DK1218378T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK00969439T 1999-10-08 2000-10-06 Tert.-butyl-(7-methylimidazo[1,2-a]pyridin-3-yl) aminderivater DK1218378T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19948434A DE19948434A1 (de) 1999-10-08 1999-10-08 Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
PCT/EP2000/009791 WO2001027109A2 (de) 1999-10-08 2000-10-06 Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridin-3-yl)-amin-derivate

Publications (1)

Publication Number Publication Date
DK1218378T3 true DK1218378T3 (da) 2003-07-21

Family

ID=7924888

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00969439T DK1218378T3 (da) 1999-10-08 2000-10-06 Tert.-butyl-(7-methylimidazo[1,2-a]pyridin-3-yl) aminderivater

Country Status (28)

Country Link
US (1) US6703404B2 (ja)
EP (1) EP1218378B1 (ja)
JP (1) JP2003511450A (ja)
KR (1) KR100793619B1 (ja)
CN (1) CN1208336C (ja)
AR (2) AR025960A1 (ja)
AT (1) ATE238304T1 (ja)
AU (2) AU7419900A (ja)
BR (1) BR0014827A (ja)
CA (1) CA2386804A1 (ja)
CO (2) CO5210861A1 (ja)
CZ (1) CZ20021241A3 (ja)
DE (2) DE19948434A1 (ja)
DK (1) DK1218378T3 (ja)
ES (1) ES2198355T3 (ja)
HK (1) HK1047749B (ja)
HU (1) HUP0203545A3 (ja)
IL (3) IL148997A0 (ja)
MX (1) MXPA02003546A (ja)
NO (1) NO20021564L (ja)
NZ (1) NZ518438A (ja)
PE (2) PE20010706A1 (ja)
PL (1) PL355109A1 (ja)
PT (1) PT1218378E (ja)
RU (1) RU2002110281A (ja)
SK (1) SK4622002A3 (ja)
WO (2) WO2001027119A2 (ja)
ZA (2) ZA200203579B (ja)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083966A (en) 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
EP1143951A3 (en) 1998-09-21 2002-02-06 University Of Florida Research Foundation, Inc. Antimalarial agents
AU2001251444A1 (en) 2000-04-10 2001-10-23 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
DE10043845A1 (de) * 2000-09-06 2002-03-14 Gruenenthal Gmbh Verfahren zur Messung der Aktivität der NO-Synthase
DE10050663A1 (de) * 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
AU2002224927A1 (en) * 2000-12-13 2002-06-24 Basf Aktiengesellschaft Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
DE10117183A1 (de) * 2001-04-05 2002-10-10 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel
DE10117184A1 (de) * 2001-04-05 2002-10-17 Gruenenthal Gmbh Substituierte Imidazol[1,2-a]-pyridin-3-yl-amid- und -aminverbindungen
DE10132726A1 (de) 2001-07-05 2003-02-27 Gruenenthal Gmbh Verwendung von substituierten gamma-Lactonverbindungen als Arzneimittel
BR0308451A (pt) 2002-03-13 2005-01-11 Euro Celtique Sa Composto, composição farmacêutica, métodos para o tratamento, prevenção ou melhoria de disfunção e método de fabricação de composto
KR20050008691A (ko) 2002-04-19 2005-01-21 셀룰러 지노믹스 아이엔씨 이미다조[1,2-a]피라진-8-일 아민, 그의 제조방법 및사용방법
US20050197435A1 (en) * 2002-06-14 2005-09-08 Dotson Darin L. Polymer additive compositions for bimolecular nucleation in thermoplastics
WO2004022562A1 (en) 2002-09-09 2004-03-18 Cellular Genomics, Inc. 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
DE10246890A1 (de) * 2002-10-08 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-alpyridin-3-yl-methylamine
WO2004058755A2 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of imidazo[1,5-a]pyridin-3-yl derivatives and related heterobicycles for targetting compounds capable of binding to g-protein coupled receptors
WO2004072080A1 (en) 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
US7259164B2 (en) 2003-08-11 2007-08-21 Cgi Pharmaceuticals, Inc. Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
WO2005034949A1 (en) 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
DE102004021716A1 (de) * 2004-04-30 2005-12-01 Grünenthal GmbH Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
DE102004044884A1 (de) * 2004-09-14 2006-05-24 Grünenthal GmbH Substituierte bizyklische Imidazo-3-yl-amin-Verbindungen
TR201910900T4 (tr) 2005-04-04 2019-08-21 Univ Florida Desferritiyokin polieter analogları.
DE102005016547A1 (de) * 2005-04-08 2006-10-12 Grünenthal GmbH Substituierte 5,6,7,8-Tetrahydro-imidazo(1,2-a)pyridin-2-ylamin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
WO2007024294A2 (en) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
RU2007147382A (ru) 2005-05-20 2009-06-27 Эррэй Биофарма Инк. (Us) Соединения, являющиеся ингибиторами raf, и способы их применения
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
WO2007019345A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Imidazopyridine derivatives as sirtuin modulating agents
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7709468B2 (en) 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
PL1973545T3 (pl) 2005-12-23 2013-05-31 Ariad Pharma Inc Bicykliczne Związki Heteroarylowe
DE102006011574A1 (de) 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
PL2001892T3 (pl) 2006-03-17 2013-09-30 Ambit Biosciences Corp Imidazolotiazolowe związki do leczenia chorób proliferacyjnych
NZ579994A (en) 2007-03-15 2011-09-30 Univ Florida Desferrithiocin polyether analogues useful in the treatment of pathological conditions responsive to chelation or sequestration of trivalent metal
WO2008134553A1 (en) * 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
GB0708188D0 (en) * 2007-04-27 2007-06-06 Merck Sharp & Dohme Therapeutic compounds
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
TW200918542A (en) 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
DE102007040336A1 (de) * 2007-08-27 2009-03-05 Johann Wolfgang Goethe-Universität Frankfurt am Main Neue Inhibitoren der 5-Lipoxygenase und deren Verwendungen
MX2010002295A (es) 2007-09-19 2010-03-22 Ambit Biosciences Corp Formas solidas que comprenden n-(5-ter-butil-isoxazol-3-il)-n´-{4- [7-(2-morfolin-4-il-etoxi) imidazo [2,1-b]-[1,3] benzotiazol-2-il] fenil} urea, composiciones de las mismas, y usos de las mismas.
NZ587039A (en) 2008-02-13 2013-01-25 Gilead Connecticut Inc 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof
CA2721670C (en) * 2008-04-15 2013-09-10 Eisai R&D Management Co., Ltd. 3-phenylpyrazolo[5,1-b]thiazole compound
WO2010032195A1 (en) * 2008-09-16 2010-03-25 Csir Imidazopyridines and imidazopyrimidines as hiv-i reverse transcriptase inhibitors
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
EP3123864A1 (en) 2008-12-08 2017-02-01 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
AU2009325133B2 (en) 2008-12-08 2016-02-04 Gilead Connecticut, Inc. Imidazopyrazine Syk inhibitors
PE20120057A1 (es) 2008-12-19 2012-02-24 Sirtris Pharmaceuticals Inc Compuestos de tiazolopiridina moduladores de sirtuina
AR078521A1 (es) * 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
AU2011226689B2 (en) 2010-03-11 2016-09-01 Kronos Bio, Inc. Imidazopyridines Syk inhibitors
MX368275B (es) 2011-12-16 2019-09-26 Univ Florida Usos de análogos de 4'-desferritiocina.
EP3632919B1 (en) 2012-04-26 2022-10-26 Bristol-Myers Squibb Company Pharmaceutical compoisitions comprising imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
US9518064B2 (en) 2012-04-26 2016-12-13 Bristol-Myers Squibb Company Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
ES2625029T3 (es) 2012-04-26 2017-07-18 Bristol-Myers Squibb Company Derivados del imidazotiadiazol como inhibidores del receptor 4 activado por proteasa (Par4) para el tratamiento de la agregación de plaquetas
CA2884767A1 (en) * 2012-11-14 2014-05-22 Stephan Bachmann Imidazopyridine derivatives
KR101810798B1 (ko) 2013-07-30 2017-12-19 질레드 코네티컷 인코포레이티드 Syk 억제제의 다형체
UA115815C2 (uk) 2013-07-30 2017-12-26 Гіліад Коннектікут, Інк. Склад на основі інгібіторів syk
JP6838966B2 (ja) 2013-11-22 2021-03-03 ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. デスフェリチオシン類似体およびその使用
MX2016007311A (es) 2013-12-04 2016-09-07 Gilead Sciences Inc Metodos para tratar canceres.
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2015123408A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
JP6602778B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Lsd1阻害剤としてのシクロプロピルアミン類
TWI664164B (zh) 2014-02-13 2019-07-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
NZ726365A (en) 2014-07-14 2018-06-29 Gilead Sciences Inc Combinations for treating cancers
SG11201708047UA (en) 2015-04-03 2017-10-30 Incyte Corp Heterocyclic compounds as lsd1 inhibitors
KR20170140306A (ko) 2015-04-27 2017-12-20 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 대사적으로 프로그램화된 금속 킬레이트화제 및 그의 용도
EP3334709A1 (en) 2015-08-12 2018-06-20 Incyte Corporation Salts of an lsd1 inhibitor
WO2017184934A1 (en) 2016-04-22 2017-10-26 Incyte Corporation Formulations of an lsd1 inhibitor
US11098043B2 (en) * 2017-07-14 2021-08-24 University Of Massachusetts Certain imidazopyridines as cyclic AMP response element binding (CREB) binding protein (CBP) inhibitors and uses thereof
AU2018321264A1 (en) 2017-08-25 2020-02-27 Kronos Bio, Inc. Polymorphs of Syk inhibitors
CA3075813A1 (en) * 2017-10-04 2019-04-11 Dana-Farber Cancer Institute, Inc. Small molecule inhibition of transcription factor sall4 and uses thereof
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CA3130848A1 (en) 2019-02-22 2020-08-27 Kronos Bio, Inc. Solid forms of condensed pyrazines as syk inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489755A (en) 1966-08-03 1970-01-13 Pfizer & Co C Imidazo (1,2-b) pyridazines
FR2463774A1 (fr) * 1979-08-21 1981-02-27 Yamanouchi Pharma Co Ltd Derives du 2-phenylimidazo(2,1-b)benzothiazole
EP0068378B1 (en) * 1981-06-26 1986-03-05 Schering Corporation Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
NZ221996A (en) * 1986-10-07 1989-08-29 Yamanouchi Pharma Co Ltd Imidazo-pyridine derivatives and pharmaceutical compositions
FR2638161B1 (fr) * 1988-10-24 1991-01-11 Centre Nat Rech Scient Nouvelles benzoyl-2 imidazo (1,2-a) pyridines et leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
JPH08333258A (ja) * 1994-12-14 1996-12-17 Japan Tobacco Inc チアジン又はチアゼピン誘導体及びそれら化合物を含有してなる一酸化窒素合成酵素阻害剤
GB9506188D0 (en) * 1995-03-27 1995-05-17 Fujisawa Pharmaceutical Co Amidine derivatives
US5908842A (en) * 1995-12-08 1999-06-01 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
WO1998006724A1 (fr) * 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Agonistes du recepteur du glutamate metabotropique
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents

Also Published As

Publication number Publication date
HK1047749A1 (en) 2003-03-07
KR20020069003A (ko) 2002-08-28
KR100793619B1 (ko) 2008-01-11
WO2001027119A2 (de) 2001-04-19
HK1047749B (zh) 2003-08-22
ZA200203581B (en) 2004-02-25
NO20021564L (no) 2002-06-04
PE20010632A1 (es) 2001-07-07
HUP0203545A3 (en) 2004-07-28
AR025960A1 (es) 2002-12-26
AU7915300A (en) 2001-04-23
ATE238304T1 (de) 2003-05-15
CN1407983A (zh) 2003-04-02
US20030022914A1 (en) 2003-01-30
PL355109A1 (en) 2004-04-05
NO20021564D0 (no) 2002-04-03
JP2003511450A (ja) 2003-03-25
WO2001027119A3 (de) 2001-10-11
EP1218378A2 (de) 2002-07-03
WO2001027109A2 (de) 2001-04-19
IL148999A0 (en) 2002-11-10
PE20010706A1 (es) 2001-08-13
DE19948434A1 (de) 2001-06-07
EP1218378B1 (de) 2003-04-23
AU7419900A (en) 2001-04-23
US6703404B2 (en) 2004-03-09
DE50001911D1 (de) 2003-05-28
ES2198355T3 (es) 2004-02-01
RU2002110281A (ru) 2003-12-20
IL148999A (en) 2007-03-08
AR025959A1 (es) 2002-12-26
BR0014827A (pt) 2003-07-08
SK4622002A3 (en) 2002-09-10
CA2386804A1 (en) 2001-04-19
ZA200203579B (en) 2003-10-29
MXPA02003546A (es) 2002-09-18
WO2001027109A3 (de) 2001-09-20
CN1208336C (zh) 2005-06-29
AU780526B2 (en) 2005-03-24
CO5251429A1 (es) 2003-02-28
CO5210861A1 (es) 2002-10-30
HUP0203545A2 (hu) 2003-02-28
PT1218378E (pt) 2003-09-30
NZ518438A (en) 2004-08-27
CZ20021241A3 (cs) 2002-08-14
IL148997A0 (en) 2002-11-10

Similar Documents

Publication Publication Date Title
DK1218378T3 (da) Tert.-butyl-(7-methylimidazo[1,2-a]pyridin-3-yl) aminderivater
NO20020687D0 (no) 3(5)-ureidopyrazolderivater, fremgangsmåte for fremstilling av disse og deres anvendelse som antitumormidler
NO20015477D0 (no) 4,5,6,7-tetrahydroindazol-derivater som anti-tumor midler
NO20020684L (no) 3(5)-aminopyrazolderivater, fremgangsmåtet for deres fremstilling og deres anvendelse som antitumormidler
NO20012057D0 (no) 2-amino-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
ATE251625T1 (de) 8-phenyl-6,9-dihydro-(1,2,4)triazolo(3,4-i)puri - 5-on derivate
DK1381363T3 (da) Imidazo[1,2-a]pyridinderivater som mGluR5-antagonister
IL160707A0 (en) 1, 8-naphthyridine derivatives as antidiabetics
NO20012058L (no) 2-ureido-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
HK1061852A1 (en) 4,5-dihydro-ih-pyrazole derivatives having cb1-antagonistic activity
AU4808300A (en) 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands
IL155974A0 (en) Novel pyridine-substituted pyrazolopyridine derivatives
DK1470124T3 (da) 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner
TR199800085A3 (tr) 8-Sübstitüye edilmis-1,3,8-triaza- spiro(4,5)dekan-4-on türevleri.
ZA200203003B (en) N-substituted carbamoyloxyalkyl-azolium derivatives.
DK1218383T3 (da) Biocykliske imidazo-5-yl-aminoderivater
TR199802520A3 (tr) 1,3,8-Triaza-spiro(4,5) dekan -4-on türevleri.
PT1210349E (pt) Pirazolo-¬4,3-d|-pirimidinas
PL349341A1 (en) Imidazo[4,5-c]-pyridine-4-on-derivatives
NO20016404D0 (no) Naftyridinderivater, fremgangsmåter for deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
GB2350361B (en) 3,4,5-tricyanophenyl derivatives
GB0214544D0 (en) 6-Crbamoylpyrimido[4,5-b]Indole derivatives
ZA200005185B (en) Indole-2,3-Dione-3-Oxime derivatives for therapeutic use.
DK1124810T3 (da) 2-amino-thiazolderivater, fremgangsmåde til deres fremstilling og deres anvendelse som antitumormidler
SI1218378T1 (en) Tert.-butyl-(7-methyl-imidazo(1,2-a)pyridine-3-yl)-amine derivatives